The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2019 | Further evidence of the benefits of double auto-SCT
Here, Michele Cavo, MD, of Bologna University School of Medicine, Bologna, Italy, discusses a retrospective analysis of three previous European trials which compared bortezomib-based vs. non-bortezomib based transplant regimens for multiple myeloma. This supported the EMN02 trial (NCT01208766) data, which suggested that double transplants provided more benefits than single transplants. This interview was recorded at the Controversies in Multiple Myeloma (COMy) 2019 meeting held in Paris, France.
